September 26, 2025 · Form 4 insider transaction
Fust Matthew K sold 16,000 shares of Crinetics Pharmaceuticals, Inc. at $44.75 per share, a transaction worth $716.0K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 4 days after the transaction.
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2024.; The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $44.75 per share.